1932

Abstract

About 25% of patients with colorectal cancer develop liver metastases after resection of the primary tumor, and surgical resection of the metastases offers the only opportunity for long-term survival. However, only 20% of patients present with resectable disease. Deciding which patients should be offered surgery, and which should receive additional treatment in the form of perioperative chemotherapy, is complex. For the majority of patients who present with technically irresectable liver-limited disease, systemic downsizing chemotherapy offers the only opportunity to reach surgery and potential cure. Molecular analysis of tumor tissue is improving patient stratification, allowing more appropriate treatment selection, but is not yet a regular part of clinical practice. Decision making is limited by a lack of clear prospective evidence, and so multidisciplinary team assessment is essential to optimize outcomes.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-062415-093510
2017-01-14
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-062415-093510.html?itemId=/content/journals/10.1146/annurev-med-062415-093510&mimeType=html&fmt=ahah

Literature Cited

  1. Jones RP, Jackson R, Dunne DF. 1.  et al. 2012. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br. J. Surg. 99:4477–86 [Google Scholar]
  2. Taylor A, Primrose LW, Kelsh MF. 2.  et al. 2012. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin. Epidemiol. 4:283–301 [Google Scholar]
  3. Jones RP, Vauthey J-N, Adam R. 3.  et al. 2012. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br. J. Surg. 99:91263–69 [Google Scholar]
  4. Adam R, De Gramont A, Figueras J. 4.  et al. 2012. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17:101225–39 [Google Scholar]
  5. Garden OJ, Rees M, Poston GJ. 5.  et al. 2006. Guidelines for resection of colorectal cancer liver metastases. Gut 55:Suppl. 3iii1–8 [Google Scholar]
  6. Wicherts DA, Miller R, de Haas RJ. 6.  et al. 2008. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann. Surg. 248:6994–1005 [Google Scholar]
  7. Schnitzbauer AA, Lang SA, Goessmann H. 7.  et al. 2012. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann. Surg. 255:3405–14 [Google Scholar]
  8. Fong Y, Fortner J, Sun RL. 8.  et al. 1999. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230:3309–18 [Google Scholar]
  9. Rees M, Tekkis PP, Welsh FKS. 9.  et al. 2008. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann. Surg. 247:1125–35 [Google Scholar]
  10. Nordlinger B, Guiguet M, Vaillant JC. 10.  et al. 1996. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77:71254–62 [Google Scholar]
  11. Zakaria S, Donohue JH, Que FG. 11.  et al. 2007. Hepatic resection for colorectal metastases: value for risk scoring systems?. Ann. Surg. 246:2183–91 [Google Scholar]
  12. Roberts KJ, White A, Cockbain A. 12.  et al. 2014. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br. J. Surg. 101:7856–66 [Google Scholar]
  13. Schreckenbach T, Malkomes P, Bechstein WO. 13.  et al. 2015. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg. Today 45:121527–34 [Google Scholar]
  14. Blazer DG, Kishi Y, Maru DM. 14.  et al. 2008. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol. 26:335344–51 [Google Scholar]
  15. Andreou A, Kopetz S, Maru DM. 15.  et al. 2012. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann. Surg. 256:4642–50 [Google Scholar]
  16. Margonis GA, Spolverato G, Kim Y. 16.  et al. 2015. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann. Surg. Oncol. 22:134158–65 [Google Scholar]
  17. Margonis GA, Kim Y, Spolverato G. 17.  et al. 2015. Association between specific mutations in KRAS Codon 12 And Colorectal Liver Metastasis. JAMA Surg 150:8722–29 [Google Scholar]
  18. Løes IM, Immervoll H, Sorbye H. 18.  et al. 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int. J. Cancer 139:3647–56 [Google Scholar]
  19. Balachandran VP, Arora A, Gonen M. 19.  et al. 2016. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases. Clin. Cancer Res. 15:222575–82 [Google Scholar]
  20. 20. National Comprehensive Cancer Network (NCCN) 2012. Clinical Practice Guidelines in Oncology; Colon Cancer v. 3. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
  21. Poston GJ, Tait D, O'Connell S. 21.  et al. 2011. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ 343:d6751 [Google Scholar]
  22. Portier G, Elias D, Bouche O. 22.  et al. 2006. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol. 24:314976–82 [Google Scholar]
  23. Mitry E, Fields ALA, Bleiberg H. 23.  et al. 2008. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol. 26:304906–11 [Google Scholar]
  24. André T, Boni C, Navarro M. 24.  et al. 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27:193109–16 [Google Scholar]
  25. Van CE, Labianca R, Bodoky G. 25.  et al. 2009. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27:193117–25 [Google Scholar]
  26. Ychou M, Hohenberger W, Thezenas S. 26.  et al. 2009. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 20:121964–70 [Google Scholar]
  27. Morris EJA, Forman D, Thomas JD. 27.  et al. 2010. Surgical management and outcomes of colorectal cancer liver metastases. Brit. J. Surg. 97:71110–18 [Google Scholar]
  28. Nordlinger B, Sorbye H, Glimelius B. 28.  et al. 2008. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:96171007–16 [Google Scholar]
  29. Nordlinger B, Sorbye H, Glimelius B. 29.  et al. 2013. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:121208–15 [Google Scholar]
  30. Sorbye H, Mauer M, Gruenberger T. 30.  et al. 2012. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg. 255:3534–39 [Google Scholar]
  31. Adam R, Bhangui P, Poston G. 31.  et al. 2010. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?. Ann. Surg. 252:5774–87 [Google Scholar]
  32. Ayez N, van der Stok EP, Grünhagen DJ. 32.  et al. 2015. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: clinical risk score as possible discriminator. Eur. J. Surg. Oncol. 41:7859–67 [Google Scholar]
  33. Primrose J, Falk S, Finch-Jones M. 33.  et al. 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:6601–11 [Google Scholar]
  34. Nordlinger B, Poston GJ, Goldberg RM. 34.  2014. Should the results of the New EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?. J. Clin. Oncol. 33:3241–43 [Google Scholar]
  35. Nordlinger B, Van Cutsem E, Gruenberger T. 35.  et al. 2009. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol. 20:6985–92 [Google Scholar]
  36. Adam R, de Gramont A, Figueras J. 36.  et al. 2015. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat. Rev. 41:9729–41 [Google Scholar]
  37. Pritchard CC, Grady WM. 37.  2011. Colorectal cancer molecular biology moves into clinical practice. Gut 60:1116–29 [Google Scholar]
  38. Hutchins G, Southward K, Handley K. 38.  et al. 2011. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29:101261–70 [Google Scholar]
  39. Roock WD, Claes B, Bernasconi D. 39.  et al. 2010. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:8753–62 [Google Scholar]
  40. Rosmarin D, Palles C, Church D. 40.  et al. 2014. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32:101031–39 [Google Scholar]
  41. Jones OM, Rees M, John TG. 41.  et al. 2005. Biopsy of resectable colorectal liver metastases causes tumour dissemination and adversely affects survival after liver resection. Br. J. Surg. 92:91165–68 [Google Scholar]
  42. Vakiani E, Janakiraman M, Shen R. 42.  et al. 2012. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 30:242956–62 [Google Scholar]
  43. Gerlinger M, Rowan AJ, Horswell S. 43.  et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:10883–92 [Google Scholar]
  44. Adam R, Avisar E, Ariche A. 44.  et al. 2001. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol. 8:4347–53 [Google Scholar]
  45. Folprecht G, Grothey A, Alberts S. 45.  et al. 2005. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol. 16:81311–19 [Google Scholar]
  46. Jones RP, Hamann S, Malik HZ. 46.  et al. 2014. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur. J. Cancer 50:91590–601 [Google Scholar]
  47. Falcone A, Ricci S, Brunetti I. 47.  et al. 2007. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol. 25:131670–76 [Google Scholar]
  48. Van CE, Köhne C-H, Láng I. 48.  et al. 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29:152011–19 [Google Scholar]
  49. Bokemeyer C, Bondarenko I, Makhson A. 49.  et al. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27:5663–71 [Google Scholar]
  50. Bokemeyer C, Bondarenko I, Hartmann JT. 50.  et al. 2011. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol. 22:71535–46 [Google Scholar]
  51. Garufi C, Torsello A, Tumolo S. 51.  et al. 2010. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br. J. Cancer 103:101542–47 [Google Scholar]
  52. 52. UK National Institute for Healthcare and Clinical Excellence 2010. Guidance TA176 https://www.nice.org.uk/guidance/ta176/documents/ta176-colorectal-cancer-first-line-cetuximab-appendix-b-proposal-paper-presented-to-the-institutes-guidance-executive2
  53. Loupakis F, Cremolini C, Masi G. 53.  et al. 2014. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N. Engl. J. Med. 371:171609–18 [Google Scholar]
  54. D'Angelica MI, Correa-Gallego C, Paty PB. 54.  et al. 2015. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann. Surg. 261:2353–60 [Google Scholar]
  55. Allen PJ, Nissan A, Picon AI. 55.  et al. 2005. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J. Am. Coll. Surg. 201:157–65 [Google Scholar]
  56. Allard MA, Sebagh M, Baillie G. 56.  et al. 2015. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann. Surg. Oncol. 22:61925–32 [Google Scholar]
  57. Vauthey J-N, Pawlik TM, Ribero D. 57.  et al. 2006. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol. 24:132065–72 [Google Scholar]
  58. Martin RCG, Scoggins CR, Schreeder M. 58.  et al. 2015. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 121:203649–58 [Google Scholar]
  59. Jones RP, Malik HZ, Fenwick SW. 59.  et al. 2015. Interim follow up results from a phase II study of neoadjuvant chemoembolization of resectable colorectal liver metastases (CRLM) with transcatheter hepatic therapy with irinotecan-eluting beads. ASCO Annu. Meet. Proc. Abstr 3588
  60. Folprecht G, Gruenberger T, Bechstein WO. 60.  et al. 2010. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:138–47 [Google Scholar]
  61. Choti MA, Thomas M, Wong SL. 61.  et al. 2015. Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann. Surg. Oncol. 23:2375–81 [Google Scholar]
  62. Ruers T, Punt C, Van CF. 62.  et al. 2012. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann. Oncol. 23:102619–26 [Google Scholar]
  63. Ruers T, Punt CJA, van CF. 63.  et al. 2015. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomised phase II study of the EORT65C-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Ann. Oncol. 26:Suppl. 4iv114–iv115 [Google Scholar]
  64. Van CE, Köhne C-H, Hitre E. 64.  et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360:141408–17 [Google Scholar]
  65. Heinemann V, von Weikersthal LF, Decker T. 65.  et al. 2014. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:101065–75 [Google Scholar]
/content/journals/10.1146/annurev-med-062415-093510
Loading
/content/journals/10.1146/annurev-med-062415-093510
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error